BioNTech

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has been approved for use in individuals from six months […]

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated to be responsible for around 17% of current Covid-19 […]

DDW’s Diana Spencer takes a closer look at three companies hoping to be the first to bring new mRNA therapeutics to the market. Although the concept of using mRNA to make therapeutics or vaccines has been around for decades, it took the urgency of a global pandemic for it to become a reality. Now, there […]

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive Officer and co-founder of BioNTech, […]

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty infringes Moderna’s patents for its […]

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19.   The lecture will be delivered in two halves by Uğur Şahin and Özlem Türeci, co-founders of BioNtech.   The first half of the lecture, titled […]

Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.  A study1 led by researchers at the University of Bristol found that two doses of Pfizer-BioNTech and AstraZeneca Covid-19 vaccines provided protection against Covid-19 infections six months after the second dose.   The study investigated how […]

Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine.  CureVac has filed the lawsuit in the German Regional Court in Düsseldorf in a move it describes as asserting […]